Metformin in Pseudomyxoma Peritonei Secondary to Appendiceal Mucinous Neoplasms

Phase 2 Recruiting 15 enrolled University of California, Irvine

NaSingle-groupOpen-labelTreatment

Summary

This is a pilot, open-label clinical trial determining the feasibility of metformin therapy in subjects with pseudomyxoma peritonei (PMP) secondary to appendiceal mucinous neoplasms (AMNs).

Timeline

Start: 2026-06-18
Primary completion: 2028-02
Completion: 2029-07

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Metformin	Small molecule	850 mg	Oral

Metformin in Pseudomyxoma Peritonei Secondary to Appendiceal Mucinous Neoplasms

Summary

Timeline

Drugs

Indications